Amgen Inc. (AMGN) stock news
The latest Amgen Inc. news and press releases. 0 news stories in the last 24 hours, 0 times its usual daily coverage. AMGN stock report · Market news
Latest news
- Amgen Has Raised Its 2026 Outlook Twice, and $1,000 From Five Years Ago Is Now Worth More Than $2,500 24/7 Wall Street, Nov 17, 4:52 PM UTC
Prolia and XGEVA are collapsing under biosimilar pressure, yet Amgen keeps lifting its guidance. Which newer drugs are filling the gap, and what could still derail a stock trading near a 52-week high? - The Winners Inside SCHD - November 2026 Seeking Alpha, Nov 17, 1:36 AM UTC
The SCHD dividend ETF has extended its year-to-date lead over SPY to more than 20%, despite recent market volatility. October was SCHD's best month of 2026, with a nearly 10% gain; 43 holdings have returned more than ... - 4 Dividend Stocks Retirees Can Buy Before They Go Ex-Dividend in the Week Ahead 247 Wallst, Nov 15, 5:00 PM UTC
Four Nasdaq payers hit their ex-dividend dates within two trading days, and one wrong move on timing forfeits the check. Which ones have the cash flow to keep paying, and where does hidden risk lurk behind the yield? - Dividend Champion, Contender, And Challenger Highlights: Week Of November 15 Seeking Alpha, Nov 13, 10:45 PM UTC
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. - Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? The Motley Fool, Nov 13, 10:42 PM UTC
Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into gene editing and pai... - Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears Benzinga, Nov 11, 3:06 PM UTC
Amgen Inc. (NASDAQ:AMGN) announced positive Phase 3 results showing dazodalibep significantly reduced systemic disease activity and key symptoms in patients with Sjögren's disease, a chronic autoimmune disease in whic... - Want $7,000 in Passive Income? Buy These 3 Dividend Stocks Today 247 Wallst, Nov 11, 2:02 PM UTC
Selling shares to pay the bills can wreck a retirement portfolio in a downturn. A biotech giant, a Coca-Cola bottler, and a Kansas utility offer another route, though one of them carries a payout ratio above its own t... - Amgen's experimental Sjogren's drug meets late-stage trial goal Reuters, Nov 11, 1:07 PM UTC
Amgen's experimental Sjogren's drug meets late-stage trial goal - Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later? 24/7 Wall Street, Nov 10, 6:17 PM UTC
One biotech pays retirees a bigger check today, while the other carries no net debt and is growing far faster. We put Amgen and Regeneron side by side on income, valuation, and growth to see which one earns a spot in ... - 3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them 24/7 Wall Street, Nov 10, 1:47 PM UTC
Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all. - The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation Fool - Investing News, Nov 8, 9:32 PM UTC
These are among the best the industry has to offer. - Amgen's Dividend Has Grown 800% Since 2011. Here's What It Pays Today 24/7 Wall Street, Nov 8, 2:09 PM UTC
Amgen has raised its payout every year since 2011, yet the pace of those raises is cooling just as patent cliffs and drug price controls close in. One number shows whether the next raise, due soon, will hold up. - Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027? The Motley Fool, Nov 5, 4:05 PM UTC
Amgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases. Pfizer maintains a massive global reach and offers a more conservative balance sheet with a lower... - 2,369 Shares of Amgen Inc. $AMGN Bought by First Nebraska Trust Co Defense World, Nov 5, 9:52 AM UTC
First Nebraska Trust Co acquired a new stake in shares of Amgen Inc. (NASDAQ: AMGN) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). T... - Blue Chips Surge Past 2.8% as VIX Drops Below 18 While Oil Sinks Nearly 8% PRNewsWire, Nov 4, 6:16 PM UTC
/PRNewswire/ -- Stock Preachers News Commentary - Wall Street roared higher this week, with the Dow jumping 2.87% in a single session to a record 53,275.11 and - Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data Benzinga, Nov 4, 5:44 PM UTC
Amgen Inc. (NASDAQ:AMGN) shares are trading close to its 52-week high on Wednesday after the company reported better-than-expected third-quarter financial results and raised its fiscal 2026 guidance. - AMGN Q3 Earnings Call Highlights Pipeline and Raised Outlook Zacks Investment Research, Nov 4, 4:02 PM UTC
Amgen raises its 2026 outlook after Q3 earnings and revenue beat estimates, as IMDELLTRA advances and MariTide offers potential long-term growth opportunities. - AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance Zacks Investment Research, Nov 4, 2:20 PM UTC
Amgen shares fall despite Q3 earnings and revenue beats. Steep declines in Prolia and Xgeva offset strong growth across key drug portfolios and raised 2026 guidance. - Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript Seeking Alpha, Nov 4, 3:45 AM UTC
Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript - What Amgen (AMGN) Said on Its Q3 Earnings Call MarketBeat, Nov 4, 1:15 AM UTC
Amgen NASDAQ: AMGN reported third-quarter revenue growth of 8% year over year to $10.4 billion, supported by broad-based demand across its portfolio and continued clinical progress in several late-stage programs. The ... - Amgen (AMGN) Reports Q3 Earnings: What Key Metrics Have to Say Zacks Investment Research, Nov 4, 12:30 AM UTC
Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and t... - Amgen (AMGN) Tops Q3 Earnings and Revenue Estimates Zacks Investment Research, Nov 3, 11:15 PM UTC
Amgen (AMGN) came out with quarterly earnings of $6.45 per share, beating the Zacks Consensus Estimate of $5.74 per share. This compares to earnings of $5.64 per share a year ago. - Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts? Zacks Investment Research, Nov 2, 6:26 PM UTC
AMGN, PFE, MRNA, NVO and VTRS are set to report this week as recent beats and key drug demand set up a pivotal Q3 earnings test for pharma giants. - Amgen Just Gave Its Shareholders Great News The Motley Fool, Nov 2, 5:25 PM UTC
Amgen's cancer drug Imdelltra has been shown to be effective in treating advanced lung cancer when paired with AstraZeneca's Imfinzi. The risk of death was cut by 58% for patients who used the combination treatment. - How to Build $6,800 a Month in Dividend Income Without Selling a Single Share 247 Wallst, Oct 30, 12:41 PM UTC
Collecting four figures a month from dividends without ever selling a share sounds straightforward until you price out what it actually costs and see which companies are holding the whole structure together. - Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know Zacks Investment Research, Oct 29, 10:51 PM UTC
The latest trading day saw Amgen (AMGN) settling at $460.73, representing a +1.97% change from its previous close. - Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming? 24/7 Wall Street, Oct 29, 9:32 AM UTC
Amgen (NASDAQ:AMGN | AMGN Price Prediction) is expected to report third-quarter results on Tuesday, November 3, after the close. The stock is up 41.28% year to date, and management has already warned that spending wil... - Amgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds? Zacks Investment Research, Oct 28, 4:21 PM UTC
Amgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth. - AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND PRNewsWire, Oct 27, 10:27 PM UTC
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the fourth quarter of 2026. The - Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue The Motley Fool, Oct 27, 7:25 PM UTC
Amgen currently looks stronger on revenue by generating a consistently larger top line in absolute terms compared to Vertex Pharmaceuticals across every observed quarter. Over roughly the last eight quarters, Amgen de...
Press releases
- AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE PRNewsWire, Nov 11, 1:00 PM UTC
Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/ -- Amgen (NASDAQ: ... - NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM PRNewsWire, Nov 9, 9:00 PM UTC
Independent VESALIUS-CV Analysis Finds Repatha Highly Cost-Effective in High-Risk Patients Without a Prior Heart Attack or Stroke Long-Term FOURIER External-Control Analysis Shows Repatha Associated With 29% Lower Ris... - REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY PRNewsWire, Nov 5, 2:00 PM UTC
Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe Study Examined More Than Half a Million Adults Living with Heart Disease Results Provide Important New C... - AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS PRNewsWire, Nov 3, 9:01 PM UTC
THOUSAND OAKS, Calif., Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026. - AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS PRNewsWire, Oct 28, 8:30 PM UTC
THOUSAND OAKS, Calif., Oct. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2026 financial results on Tuesday, November 3, 2026, after the close of the U.S. financial... - AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 PRNewsWire, Oct 27, 8:00 PM UTC
Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness New Long-Term UPLIZNA Data in... - AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS PRNewsWire, Oct 26, 9:52 PM UTC
THOUSAND OAKS, Calif., Oct. 26, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of David W. - IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER PRNewsWire, Oct 24, 2:30 PM UTC
Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Symposium and Simul... - AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026 PRNewsWire, Oct 20, 8:15 PM UTC
THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ESMO) 2026 on Satur... - TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS PRNewsWire, Oct 20, 1:00 PM UTC
Symptom Improvements Versus Placebo at Week 24 Were Sustained Through Week 52 Statistically Significant Total Endoscopic Remission with No Visible Inflammation or Fibrosis Attained Versus Placebo at Week 52 THOUSAND O... - AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE PRNewsWire, Sep 22, 1:00 PM UTC
Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living ... - FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA® PRNewsWire, Sep 14, 1:00 PM UTC
Update Supports Broader Access to IMDELLTRA in Community Settings for People Living with Extensive-Stage Small Cell Lung Cancer THOUSAND OAKS, Calif., Sept. 14, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced...
Headlines link to their publishers. Research data, not investment advice.